1.Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89 (6): 2745- 2749.
2.Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005; 352 (12): 1223- 1236.
3.Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18 (6): 7740- 7800.
4.Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996; 335 (9): 617- 623.
5.Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Strauss III JF, Mcallister JM. Differential activity of the cytochrome P450 17 -hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab. 2000; 85 (6): 2304- 2311.
6.Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003; 80 (1): 123- 127.
7.Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91 (1): 336- 340.
8.Murri M, Luque-Ram rez M, Insenser MA, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update. 2013; 19 (3): 268- 288.
9.Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015; 36 (5): 487- 525.
10.Hosseinkhani A, Asadi N, Pasalar M, Mohammad MZ. Insights of traditional Persian medicine to polycystic ovary syndrome and its management. Planta Medica Int Open. 2017; 4 (S01): 1- 200.
11.Tomatis V, Wassell S, Venables M, Walker C, Ray S, Siervo M, et al. Effects of green tea and coffee polyphenols on cardiometabolic function in women with polycystic ovary syndrome. FASEB J. 2015; 29 (1 Supplement): LB271.
12.Banaszewska B, Wroty ska-Barczy ska J, Spaczynski RZ, Pawelczyk L, Duleba AJ. Effects of resveratrol on polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2016; 101 (11): 4322- 4328.
13.Choubey S, Varughese LR, Kumar V, Beniwal V. Medicinal importance of gallic acid and its ester derivatives: a patent review. Pharm Pat Anal. 2015; 4 (4): 305- 315.
14.Asnaashari M, Farhoosh R, Sharif A. Antioxidant activity of gallic acid and methyl gallate in triacylglycerols of Kilka fish oil and its oil-in-water emulsion. Food Chem. 2014; 159:439- 444.
15.Shahidi F, Ambigaipalan P. Phenolics and polyphenolics in foods, beverages and spices: antioxidant activity and health effects A review. J Funct Foods. 2015; 18: 820- 897.
16.Jamil F, Rassouli MB, Shahri NM, Dehghani H. Study of the effects of hyperglycemia and insulin therapy on uterus histology and estrous cycle in wistar rat. J Cell Tissue. 2013; 4 (2): 149- 157.
17. Sadoughi S. Effects of crocin on ovarian follicle and serum sex hormone in letrozole- induced polycystic ovarian syndrome in rat model. Ardabil Med Sci Univ J. 2017; 17 (2): 198- 210.
18. Sadoughi S, Rahbarian R, Jahani N, Shazdeh S, Hossein Zadeh Saljoughi S, Daee M. Effect of aqueous extract of artemisia absinthium L. on sex hormones, inflammatory cytokines and oxidative stress indices of ovarian tissue in polycystic ovary syndrome rat model. JBUMS. 2017; 19 (7): 50- 56.
19.Doldi N, Persico P, Di Sebastiano F, Marsiglio E, Ferrari A. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecol Endocrinol. 2006; 22 (5): 235- 238.
20.Hyderali BN, Mala K. Oxidative stress and cardiovascular complications in polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2015; 191: 15- 22.
21. Paixão L, Ramos RB, Lavarda A, Morsh DM, Spritzer PM. Animal models of hyperandrogenism and ovarian morphology changes as features of polycystic ovary syndrome: a systematic review. Reprod Biol Endocrinol. 2017; 15 (1): 12.
22.Mansouri MT, Farbood Y, Sameri MJ, Sarkaki A, Naghizadeh B, Rafeirad M. Neuroprotective effects of oral gallic acid against oxidative stress induced by 6-hydroxydopamine in rats. Food Chem. 2013; 138: 1028- 1033.
23.Reckziegel P, Dias VT, Benvegnú DM, Boufleur N, Barcelos RCS, Segat HJ, et al. Antioxidant protection of gallic acid against toxicity induced by Pb in blood, liver and kidney of rats. Toxicol Rep. 2016; 3: 351- 356.
24.Papalou O, Victor VM, Diamanti-Kandarakis E. Oxidative stress in polycystic ovary syndrome. Curr Pharm Des. 2016; 22 (18): 2709- 2722.
25.Dandona P, Dhindsa S, Aljada A, Garg R. Insulin as an anti-inflammatory and antiatherosclerotic hormone. Clin Cornerstone. 2003; 5: S13- 20.
26.Boots CE, Jungheim ES. Inflammation and human ovarian follicular dynamics. Semin Reprod Med. 2015; 33 (4): 270- 275.
27.Rafiei S, Edalatmanesh MA. The effect of exercise training on serum level of β- estradiol, testosterone, and cognitive deficit in rats with letrozole- induced polycystic ovary syndrome. Shefaye Khatam J. 2016; 4 (2): 8- 11- 8.